University of Minnesota
University Relations

Minnesota Supercomputing Institute

Log out of MyMSI

Research Abstracts Online
January - December 2011

Main TOC ...... Next Abstract

University of Minnesota Twin Cities
Academic Health Center
Masonic Cancer Center

PI: Scott M. Dehm

Role of the Androgen Receptor in Prostate Cancer

The androgen receptor is a nuclear steroid receptor transcription factor that responds to the physiologic androgens testosterone and dihydrotestosterone. Traditionally, treatment for metastatic prostate cancer has depended on blocking the production or action of these androgens in order to inhibit the growth and survival promoting functions of the androgen receptor. Androgen depletion is therefore one of the earliest examples of targeted cancer therapy. The primary limitation of androgen depletion is that prostate cancer will eventually develop resistance and recur with a lethal castration-resistant phenotype. The Dehm laboratory studies the changes that occur in the therapeutic target (the androgen receptor, AR) in response to the targeted therapy (androgen depletion) to understand the mechanisms underlying this progression to therapy-resistant disease. They are pursuing various genomic tools to study prostate cancer progression in clinical prostate cancer specimens, and collaborate with MSI and the Masonic Cancer Center Bioinformatics Core Resource personnel to obtain, analyze, and integrate this information. The ultimate goal is to develop new AR-targeted therapies that could more effectively and durably suppress prostate cancer growth.

Group Members

Majid Alsagabi, Graduate Student
Siu Chiu Chan, Research Associate
Flora Danhua Fan, Graduate Student
Tae Hyun Hwang, Graduate Student
Kevin A.T. Silverstein, Faculty Collaborator
Ahmed H. Tewfik, Computer and Electrical Engineering Department, University of Texas, Austin, Texas